Abstract：
BACKGROUND: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.
METHODS: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.
RESULTS: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.
CONCLUSIONS: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.
METHODS: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.
RESULTS: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.
CONCLUSIONS: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.
摘要：
目的：综合分子肿瘤谱在癌症患者的治疗中被广泛使用。分子肿瘤委员会根据测试结果设计治疗策略。在此设置中，跨部门分子肿瘤委员会交流平台Deutschland（TEAM-D）旨在推动点对点交流，以连接该领域的专家。
方法：在第一次虚拟TEAM-D会议期间，来自16所德国大学和5所非学术机构的参与者讨论了5例PIK3CA热点突变病例.此外，提出了一个说明性的案例插图。
结果：总体而言，德国护理人员在施用标签外PIK3CA抑制剂方面表现出克制，并支持在这种情况下进行临床试验。
结论：在精准肿瘤学的背景下，TEAM-D可在德国医疗保健系统的不同部门进行虚拟病例讨论。以PIK3CA热点突变为例,TEAM-D展示了整合来自不同医疗保健专业人员的知识的价值。
方法：在第一次虚拟TEAM-D会议期间，来自16所德国大学和5所非学术机构的参与者讨论了5例PIK3CA热点突变病例.此外，提出了一个说明性的案例插图。
结果：总体而言，德国护理人员在施用标签外PIK3CA抑制剂方面表现出克制，并支持在这种情况下进行临床试验。
结论：在精准肿瘤学的背景下，TEAM-D可在德国医疗保健系统的不同部门进行虚拟病例讨论。以PIK3CA热点突变为例,TEAM-D展示了整合来自不同医疗保健专业人员的知识的价值。
